Early Myocarditis Onset After Immunotherapy Signals Higher Risk of Fatality, Study Finds

Patients who develop myocarditis within the first month of starting immune checkpoint inhibitor (ICI) therapy face a significantly higher risk of dying from this rare but potentially devastating immune-related side effect, according to new research presented at the annual meeting of the  American Association for Cancer Research (AACR) held April 17 – 22, 2026, in San Diego, CA.

Immune checkpoint inhibitors (ICI) have transformed cancer treatment, but on rare occasions, they can trigger myocarditis—a dangerous inflammation of the heart muscle. Hassan M. Abushukair, MD, a postdoctoral researcher at the Oklahoma University Stephenson Cancer Center, and his team analyzed almost 5,000 cases in the World Health Organization’s global pharmacovigilance database to better understand the timing and risk factors for fatal myocarditis linked to these drugs.

The study found that patients whose myocarditis began within the first 30 days of ICI treatment were 59% more likely to die from the condition compared to those whose onset occurred one to three months after starting therapy. The risk was 56% higher compared to those whose myocarditis developed three to twelve months after treatment initiation.*

“Clinicians should be especially vigilant during the first month of ICI therapy,” Abushukair said.

“An early warning sign like myocarditis in that window is a flashing red light for close monitoring and intervention,” he added.

Triple-M Overlap Syndrome: A Deadly Combination
The research also highlighted the dangers of ‘triple-M overlap syndrome’ (TMOS), where myocarditis occurs alongside myositis (muscle inflammation) and myasthenia gravis (nerve-muscle communication disruption). TMOS was linked to the highest myocarditis-specific fatality rate at 38%, compared to 21.2% for myocarditis alone.

The researchers found that TMOS was more common in melanoma patients and in men treated with dual ICI therapy.

To help identify patients at greatest risk, the researchers developed a machine learning algorithm to predict fatality from ICI-induced myocarditis using clinical data. The tool demonstrated strong accuracy in distinguishing fatal from nonfatal cases and could eventually aid clinicians in real-time patient monitoring and risk stratification.

Key Findings

• Of 2,641 myocarditis cases, 27.6% overlapped with myositis and/or myasthenia gravis.
• Myocarditis associated with TMOS occurred earlier (median onset: 26 days) than myocarditis alone (median: 60.8 days).
• Early-onset myocarditis (within 30 days of ICI start) was the strongest predictor of fatality.
• Hepatitis was the most common additional immune-related side effect in TMOS cases.

Implications for Practice
This study—one of the largest to date on ICI-induced myocarditis—suggests that the first month of ICI therapy is a critical period for risk assessment. Clinicians are encouraged to closely monitor for cardiac and neuromuscular symptoms during this window, especially in patients receiving combination immunotherapy or those with melanoma.

Abushukair and colleagues hope that their machine learning model, once validated, will become a bedside tool to help guide risk-based monitoring and interventions, ultimately making ICI therapy safer for cancer patients.

Study Limitations
The retrospective and descriptive nature of the study, as well as heterogeneity in the global data set, are acknowledged limitations. Incomplete treatment information was also a challenge.
__

Note:* For clinicians and patients navigating the promise and risks of immunotherapy, these findings highlight the need for vigilance and early intervention when warning signs appear—especially in the crucial first month of treatment.

Reference
[1] Abushukair HM, Alghamdi E, Jung W, Laharwal M, Gundroo H, Pannu S, Tan AC, Funchain P, Abdel-Wahab N, Sharon E, Johnson DB, Amin H. Nassar AH, Al-Harbi F, Oh TG, Naqash AR. Clinical characterization of immune checkpoint inhibitor-induced myocarditis and the triple M overlap syndrome. In: Proceedings of the 117th Annual Meeting of the American Association for Cancer Research; 2026 April 17-22; San Diego, CA.: AACR; 2026. Abstract nr 5212 / 3

Featured image: San Diego, CA – The AACR 2026 Annual Meeting –  Photo courtesy © 2026 AACR/Luke Franke. Used with permission

DOI